solid limit covid impact management indic
mid-april appear bottom eylea demand
expect trough management plan initi first
trial june remain commit
manufactur risk base initi data pt
 unit state america
ep beat total revenu ahead driven
eylea dupix management announc guidanc
includ non-gaap unreimburs guidanc non-gaap
sg guidanc first time non-gaap cog guidanc
first time cocm guidanc non-
effect tax rate guidanc capit expenditur guidanc
previous management expect oper incom
expens new line item rang incom year
final management expect impact peak
takeaway call management leverag
genet human velocimmun mice platform convalesc plasma
human volunt develop antivir antibodi cocktail could
avail earli late summer fall antibodi cocktail intend
act prophylact treatment risk infect
alreadi infect symptomat management highlight import treat
earli base experi ebola management lead back-up
 june management plan initi three set studi
prophylactic/prevent set peopl high-risk symptomat
peopl requir oxygen support hospit patient
standard-of-car management manufactur risk initi data could come
earli month two trial initi base earli result management
expect hundr thousand dose avail end august
management note upstat new york manufactur facil alon
potenti capac produc dose per month peak management believ
need maintain high antibodi level least month
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
prophylact set highlight abl maintain protect
antibodi rsv sever month eyea neg
impact eylea sale last two week march first two week
april management announc rebound recent two week management report
greater neg impact diabet eye diseas patient given comorbid
risk april demand y/i novarti cover mark purcel
recent initi review beovu includ extern safeti review
committe confirm rare advers event retin vascul
and/or retin vascular occlus without presenc intraocular
inflamm may result sever vision loss initi safeti
inform updat prescrib inform management reiter eylea
similar side effect dupix rate new start april
impact pdufa date children age yoa
moderate-to-sever atop dermat libtayo management report
encourag phii result open-label studi basal cell carcinoma
patient progress respond hedgehog pathway inhibitor
therapi sonidegib vismodegib object respons rate orr
patient local advanc diseas estim
durat respons dor exceed yr respond base
preliminari analysi patient metastat diseas orr
dor exceed yr respond new safeti
signal total patient discontinu due ae management plan
submit data phiii fasinumab studi osteoarthr pain
expect readout
stock lever covid data base biz stabil good news investor
concern eylea would face outsiz pressur due elderli
popul need in-offic inject management commentari suggest
impact modest sinc start see recoveri believ
stabil base busi coupl continu growth dupix
provid signific downsid support importantli market remain
focus covid antibodi treatment impact rel
valuat believ antibodi therapi greatest potenti
signific mortal benefit key covid therapeut thu
sure financi impact believ likelihood success
high amend model rais eylea estim exhibit given
management posit commentari adjust model base management guidanc
higher eylea revenu project drive bulk pt increas along
increas dupix revenu lower sg cost lower tax rate pt
eylea dupix oncolog pipelin drive risk-reward
deriv pt discount analysi use wacc
termin growth rate
ew regeneron believ
potenti upsid factor success
libtayo nsclc earli stage
bi-spec pipelin off-set potenti
risk intern refer price
pressur eylea
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario
price either three-month one-year time view explan option probabl methodolog
strong dupix growth success
strong dupix growth success
oncolog pipelin limit eylea
oncolog pipelin limit eylea
competit biosimilar brand
competit biosimilar brand
competit assum us
eylea row eylea
kevzara us sale
us dupilumab sale
dupix growth multipl indic
dupix growth multipl indic
us eylea row eylea
us dupilumab sale
eylea pressur limit dupix growth
eylea pressur limit dupix growth
outsid core indic assum
outsid core indic assum
us eylea row eylea
us praluent
modest row praluent sale
dupilumab sale
phii data test pozelimab pnh
updat result r/r fl dlbcl car-t
nave post-car-t
report dose escal interim data phi
trial r/r multipl myeloma
garetosmab submit patient fibrodysplasia
initi phii trial gener lipodystrophi
driver includ impact potenti eylea
competit updat dataset
oncolog pipelin growth dupix
view explan region hierarchi
research highest favor quintil
signic implement part
signic eylea competit sale
signic penetr libtayo nsclc
eylea face brand biosimilar competit
take signic share
oncolog pipelin fail perform
dupix atten earlier expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
